ArticleJTO clinical and research reports2022

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC.

Christopher A Lemmon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.